New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 31, 2013
06:43 EDTCYH, FMS, THC, HMA, DVAMedicare to lower payments for dialysis, Washington Post reports
Medicare is beginning the process of lowering the amount it pays to hospitals and clinics for kidney dialysis drugs, according to The Washington Post. The reduced payments aren't expected to take effect until next year, however, the newspaper added. Reference Link
News For DVA;THC;CYH;HMA;FMS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 23, 2015
08:08 EDTCYHCommunity Health reports agreement for purchase of interest in Metro Health
Subscribe for More Information
January 21, 2015
10:01 EDTFMSOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
07:09 EDTFMSFresenius Medical downgraded to Equal Weight from Overweight at Barclays
06:40 EDTFMSFresenius Medical downgraded to Neutral from Buy at UBS
UBS downgraded Fresenius Medical to Neutral citing limited upside to shares.
January 20, 2015
07:18 EDTCYHCommunity Health sees Q4 EPS $1.23, consensus $1.20
Sees Q4 net operating revenue approx. $4.9B, consensus $5.06B. Excluding acquisition and integration expenses from the acquisition of Hospital Management Associates, legal expenses related to the HMA legal proceedings underlying the CVR agreement, and expenses related to other government legal settlements, adjusted EBITDA is expected to be approximately $785M for the three months ended December 31, 2014.
07:18 EDTCYHCommunity Health Sees FY14 EPS $3.29, consensus $3.21
Subscribe for More Information
January 16, 2015
10:47 EDTDVA, CYH, THCBofA/Merrill healthcare facilities analyst analyst/industry conference call
Healthcare Facilities & Managed Care Analyst Bressler discusses the legislative and regulatory outlook for the industry for 2015 on an Analyst/Industry conference call to be held on January 23 at 2 pm.
January 15, 2015
09:17 EDTFMSFlamel Technologies weakness creates buying opportunity, says SunTrust
Subscribe for More Information
08:47 EDTFMSFlamel Technologies price target lowered to $17 from $22 at Roth Capital
Roth Capital cut its price target on Flamel (FLML) after the FDA approved Fresenius Kabi's (FMS) New Drug Application for neostigmine methylsulfate, a drug which Flamel currently markets as Bloxiverz. Roth expects eostigmine to become a two player market, but adds that price increases by Flamel could mitigate the negative impacts on Flamel's growth. The firm keeps a Buy rating on Flamel.
January 13, 2015
07:42 EDTFMSJPMorgan to hold a conference
33rd Annual Healthcare Conference is being held in San Francisco on January 12-15 with webcasted company presentations to begin on January 13 at 10:30 am; not all company presentations may be webcasted. Webcast Link
January 12, 2015
08:33 EDTTHCTenet sees FY15 adjusted EPS $1.32-$2.40, consensus $2.70
Subscribe for More Information
08:31 EDTTHCTenet sees FY15 adjusted EBITDA $2.05B-$2.15B
Subscribe for More Information
07:17 EDTCYHJPMorgan to hold a conference
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use